Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT 596

Next Previous
Search
Drug Profile

FT 596

Alternative Names: CAR19+hnCD16+IL-15RF engineered iPSC-derived NK cell therapy; FT-596

Latest Information Update: 26 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fate Therapeutics; University of Minnesota
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Nov 2023 University of Minnesota completes a phase I trial for B-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT04555811)
  • 27 Sep 2023 Fate Therapeutics terminates a phase-I trial in B-cell lymphoma and Chronic lymphocytic leukaemia in USA (NCT04245722)
  • 02 Feb 2023 University of Minnesota suspends a phase I trial for B-cell lymphoma (In adults, In the elderly, Combination therapy, Second-line therapy or greater) in USA (Parenteral) due to amendment pending reason (NCT04555811)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top